A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT ID: NCT06007690

Last Updated: 2025-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-06

Study Completion Date

2028-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, sham-controlled, subject-, assessor-, and Sponsor- masked trial to establish the safety and efficacy of bel-sar treatment via suprachoroidal (SC) administration in subjects with primary IL/CM. Bel-sar treatment incorporates administration of bel-sar drug product using a suprachoroidal space (SCS) microinjector and activation of bel-sar by a laser photoactivation device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Choroidal Melanoma Indeterminate Lesions Uveal Melanoma Ocular Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Subject, Assessor, and Sponsor masked trial.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High dose bel-sar treatment arm & laser application

High dose of bel-sar + laser application

Group Type EXPERIMENTAL

Bel-sar

Intervention Type DRUG

Bel-sar via suprachoroidal administration followed by laser application.

Suprachoroidal Microinjector

Intervention Type DEVICE

Suprachoroidal injection device

Infrared Laser

Intervention Type DEVICE

Laser application

Low dose bel-sar treatment arm & laser application

Low dose of bel-sar + laser application

Group Type EXPERIMENTAL

Bel-sar

Intervention Type DRUG

Bel-sar via suprachoroidal administration followed by laser application.

Suprachoroidal Microinjector

Intervention Type DEVICE

Suprachoroidal injection device

Infrared Laser

Intervention Type DEVICE

Laser application

Sham control arm & sham laser

Sham injection + sham laser

Group Type SHAM_COMPARATOR

Sham Infrared Laser

Intervention Type DEVICE

Sham laser application

Sham Microinjector

Intervention Type DEVICE

Sham injection device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bel-sar

Bel-sar via suprachoroidal administration followed by laser application.

Intervention Type DRUG

Suprachoroidal Microinjector

Suprachoroidal injection device

Intervention Type DEVICE

Infrared Laser

Laser application

Intervention Type DEVICE

Sham Infrared Laser

Sham laser application

Intervention Type DEVICE

Sham Microinjector

Sham injection device

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AU-011 SCS Microinjector

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)
* Have no evidence of metastatic disease confirmed by imaging
* Be treatment naive for IL/CM (subjects who received PDT may be eligible)

Exclusion Criteria

* Have known contraindications or sensitivities to the study drug or laser
* Active ocular infection or disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aura Biosciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Aura Biosciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Emory Eye Center

Atlanta, Georgia, United States

Site Status RECRUITING

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status RECRUITING

Tufts Medical Center New England Eye Center

Boston, Massachusetts, United States

Site Status RECRUITING

Massachusetts Eye and Ear

Boston, Massachusetts, United States

Site Status RECRUITING

W.K. Kellogg Eye Center - University of Michigan

Ann Arbor, Michigan, United States

Site Status RECRUITING

Retina Consultants of Alabama

Birmingham, Alabama, United States

Site Status WITHDRAWN

UCSD Shiley Eye Institute, Jacobs Retina Center

La Jolla, California, United States

Site Status RECRUITING

Doris Stein Eye Research Center

Los Angeles, California, United States

Site Status NOT_YET_RECRUITING

Stanford University School of Medicine

Palo Alto, California, United States

Site Status RECRUITING

Retinal Consultants Medical Group, Inc.

Sacramento, California, United States

Site Status RECRUITING

Bascom Palmer Eye Institute

Miami, Florida, United States

Site Status RECRUITING

Retina Associates of Florida, PA

Tampa, Florida, United States

Site Status RECRUITING

Associated Retinal Consultants (ARC) P.C.

Royal Oak, Michigan, United States

Site Status RECRUITING

Mayo Clinic

Rochester, Minnesota, United States

Site Status RECRUITING

Washington University

St Louis, Missouri, United States

Site Status RECRUITING

Nebraska Medicine's Truhlsen Eye Institute

Omaha, Nebraska, United States

Site Status RECRUITING

Columbia University Irving Medical Center

New York, New York, United States

Site Status RECRUITING

Duke Eye Center

Durham, North Carolina, United States

Site Status RECRUITING

Cole Eye Institute

Cleveland, Ohio, United States

Site Status RECRUITING

Dean McGee Eye Institute

Oklahoma City, Oklahoma, United States

Site Status RECRUITING

Retina Consultants of Oklahoma

Oklahoma City, Oklahoma, United States

Site Status RECRUITING

Shields & Shields PC-Wills Eye Institute

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Retina Consultants of Carolina

Greenville, South Carolina, United States

Site Status RECRUITING

Southeastern Retina Associates

Chattanooga, Tennessee, United States

Site Status RECRUITING

Tennessee Retina, PC

Nashville, Tennessee, United States

Site Status RECRUITING

Austin Retina Associates

Austin, Texas, United States

Site Status RECRUITING

Texas Retina Associates

Dallas, Texas, United States

Site Status RECRUITING

UT, Southwestern Medical Center

Dallas, Texas, United States

Site Status RECRUITING

Retina Associates of South Texas, P.A.

San Antonio, Texas, United States

Site Status RECRUITING

Retina Center of Texas

Southlake, Texas, United States

Site Status RECRUITING

Retina Consultants of Texas

The Woodlands, Texas, United States

Site Status RECRUITING

Retina Associates of Utah

Salt Lake City, Utah, United States

Site Status RECRUITING

Vitreoretinal Associates of Washington

Bellevue, Washington, United States

Site Status RECRUITING

University of Washington Medical Center

Seattle, Washington, United States

Site Status RECRUITING

University of Wisconsin Madison

Madison, Wisconsin, United States

Site Status RECRUITING

Terrace Eye Centre

Brisbane, Queensland, Australia

Site Status RECRUITING

Eye Research Australia

East Melbourne, Victoria, Australia

Site Status RECRUITING

Medical University Graz

Graz, , Austria

Site Status RECRUITING

Medizinische Universität Wien, Department of Ophthalmology and Optometry

Vienna, , Austria

Site Status RECRUITING

UZ Leuven

Leuven, , Belgium

Site Status RECRUITING

Serac Eye and Skin Care Centre

Calgary, Alberta, Canada

Site Status RECRUITING

Princess Margaret Eye Tumour Clinic

Toronto, Ontario, Canada

Site Status NOT_YET_RECRUITING

Centre Hospitalier de l'Universite Laval

Québec, Quebec, Canada

Site Status RECRUITING

Fakultni Thomayerova nemocnice

Prague, Krč, Czechia

Site Status RECRUITING

Fakultni nemocnice Plzen

Pilsen, Plzenský Kraj, Czechia

Site Status RECRUITING

Ustredni vojenska nemocnice Vojenska fakultni nemocnice Praha

Prague, , Czechia

Site Status RECRUITING

Centre Hospitalier Universitaire de Nice

Nice, Cedex 1, France

Site Status RECRUITING

Charité - Universitätsmedizin Berlin KöR

Berlin, , Germany

Site Status RECRUITING

Uniklinikum Hamburg Eppendorf

Hamburg, , Germany

Site Status RECRUITING

Universitätsklinikum Schleswig-Holstein Klinik für Augenheilkunde

Lübeck, , Germany

Site Status RECRUITING

Klinikum der LMU Muenchen

München, , Germany

Site Status RECRUITING

Universitätsklinikum Tübingen

Tübingen, , Germany

Site Status RECRUITING

The Chaim Sheba Medical Center

Tel-Hashomer, Central District, Israel

Site Status RECRUITING

Hadassah Medical Center, Ein-Karem

Jerusalem, Jerusalem, Israel

Site Status RECRUITING

AOUC Azienda Ospedaliero-Universitaria Careggi

Florence, , Italy

Site Status RECRUITING

Istituto Nazionale dei Tumori, Fondazione IRCCS

Milan, , Italy

Site Status RECRUITING

Ospedale Fatebenefratelli e Oftalmico, ASST Fatebenefratelli Sacco

Milan, , Italy

Site Status RECRUITING

Universita'Cattolica Del Sacro Cuore - UNICATT

Roma, , Italy

Site Status RECRUITING

Leids Universitair Medisch Centrum (LUMC)

Leiden, , Netherlands

Site Status RECRUITING

Erasmus MC

Rotterdam, , Netherlands

Site Status RECRUITING

Auckland Eye Ltd

Auckland, , New Zealand

Site Status RECRUITING

Hospital Universitario de Bellvitge

Barcelona, , Spain

Site Status RECRUITING

Hospital Provincial de Conxo

Santiago de Compostela, , Spain

Site Status RECRUITING

Hospital Universitario Y Politécnico La Fe

Valencia, , Spain

Site Status RECRUITING

Moorfields Eye Hospital NHS Foundation Trust

London, , United Kingdom

Site Status RECRUITING

Nhs Foundation Trust - Royal Hallamshire Hospital

Sheffield, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Canada Czechia France Germany Israel Italy Netherlands New Zealand Spain United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Medical Monitor

Role: CONTACT

617-500-8864

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AU-011-301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.